Loading
A phase 3 trial of Tislelizumab in non-small-cell lung cancer and small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT07170995 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 460 participants planned, started 2025-10-22 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-8068，adebelizumab and platinum-based chemotherapy, tislelizumab, and platinum-based chemotherapy. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Tislelizumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.
Shares Tislelizumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Tislelizumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Tislelizumab, Immune checkpoint inhibitors.
Shares Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.